Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Accumulated Expenses (2021 - 2022)

Acro Biomedical has reported Accumulated Expenses over the past 2 years, most recently at $19.8 million for Q1 2022.

  • Quarterly results put Accumulated Expenses at $19.8 million for Q1 2022, changed N/A from a year ago — trailing twelve months through Mar 2022 was $19.8 million (changed N/A YoY), and the annual figure for FY2021 was $23.8 million, changed.
  • Accumulated Expenses for Q1 2022 was $19.8 million at Acro Biomedical, down from $23.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ACBM hit a ceiling of $23.8 million in Q4 2021 and a floor of $18.5 million in Q2 2021.